Viatris

Earlier in 2023, the integration process included over 70 emerging markets in July, the North America business in September, and the European business in November

Viatris sells API & women's healthcare business in India for $1.2 billion

Viatris has also sold its OTC (over- the- counter) business in Europe and commercialisation rights in a few non-core markets as part of a global divestiture drive to pare debt.

Biocon Biologics completes integration of Viatris' Biosimilars business in North America ahead of schedule

In the Apr-Jun quarter of the fiscal year, Biocon’s biosimilar division emerged as the driving force behind its top-line expansion

Viatris gets US FDA's tentative approval for pediatric formulation of HIV medicine

The medicine is indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months weighing at least 6 kg to less than 25 kgs

Biocon aims to become the largest biosimilar company globally: Kiran Mazumdar-Shaw

Biocon Chairman sees biologics business hitting Rs 2,000 crore in the fourth quarter; says there's a need to build robust regulatory system to curb instances of adulteration of drugs by Indian pharma firms.

Viatris acquisition allows us to offer a full solution to healthcare systems globally: Biocon Biologics CEO 

Biosimilars are clearly the answer to some of the challenges before global healthcare agencies, says Shreehas Tambe.

Biocon Biologics completes acquisition of Viatris' global biosimilars business

In February this year, Biocon Biologics inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.33 billion (about Rs 24,990 crore).

Biocon’s expensive bet ignores execution risks

Apart from the near-term financial impact of the debt, investors need to watch out for the scale-up of the biosimilars business in the US and global markets

Biocon Biologics, Viatris launch biosimilar insulin glargine in US

Biocon Biologics and Viatris Inc have launched Semglee (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Biocon Biologics, Viatris receive EC nod for biosimilar Bevacizumab

The nod came following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, it said.